Skip to main content
. Author manuscript; available in PMC: 2014 Jul 14.
Published in final edited form as: Sci Transl Med. 2011 Jul 20;3(92):92ra64. doi: 10.1126/scitranslmed.3002097

Figure 3. AAV9-S100A1 gene therapy rescues cardiac function and reverses myocardial remodelling in failing myocardium.

Figure 3

(A–E) 12 weeks after AAV9-S100A1 treatment, failing hearts with reconstituted S100A1 expression (n=9) exhibit restored LV function, compared to HF-saline (n=14) or HF-Luc (n=9). (F–H) S100A1 gene therapy attenuated LV remodelling, which was corroborated by reversed fetal gene activation. †P<0.05 sham vs. HF-saline and HF-Luc, *P<0.05 HF-S100A1 vs. HF-saline and HF-Luc, **P<0.05 sham vs. all other groups. mRNA levels were assessed in the LV anterior wall of 5 animals in each group and normalized to sham. EF, ejection fraction; EDP, enddiastolic pressure; HW/BW, heart weight/body weight; EDD, enddiastolic diameter; BNP, brain natriuretic peptide. Data are presented as mean±SEM.